Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis

References

• Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16: 592–9
   PubMed Web of Science ®Google Scholar
• Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109:2492–9
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–24
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–6
   PubMed Web of Science ®Google Scholar
• Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000;109:307–14
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585–92
   PubMed Web of Science ®Google Scholar
• Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007;24:486–93
   PubMed Web of Science ®Google Scholar
• Hollander-Rodriguez JC, Calvert JF, Jr. Hyperkalemia. Am Fam Physician 2006;73:283–90
   PubMed Web of Science ®Google Scholar
• Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol 2005;42 Suppl 1:S50–6
   PubMedGoogle Scholar
• Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221–9
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11–20
   PubMed Web of Science ®Google Scholar
• Birkenhager WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007;370:195–6
   PubMed Web of Science ®Google Scholar
• Izzo JL, Jr., Weinberg MS, Hainer JW, et al. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) 2004;6:485–93
   PubMedGoogle Scholar
• Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839–45
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21
   PubMed Web of Science ®Google Scholar
• Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998;158:26–32
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219–24
   PubMed Web of Science ®Google Scholar
• Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277:1624–32
   Google Scholar
• Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004;43:155–61
   PubMed Web of Science ®Google Scholar
• Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med 2000;160:2429–36
   PubMed Web of Science ®Google Scholar
• Krishna GG, Kapoor SC. Potassium depletion exacerbates essential hypertension. Ann Intern Med 1991;115:77–83
   PubMed Web of Science ®Google Scholar
• Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217–26
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor A, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190–8
   PubMed Web of Science ®Google Scholar
• Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589–99
   PubMed Web of Science ®Google Scholar
• Sica D, Gradman AH, Lederballe O, et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during longterm (52 weeks) treatment of hypertension. Eur Heart J 2006;27(Suppl):121 P797
   Google Scholar
• Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002;288:1882–8
   PubMed Web of Science ®Google Scholar
• Stamler R. Implications of the INTERSALT study. Hypertension 1991;17(1 Suppl):I16–20
   PubMed Web of Science ®Google Scholar